|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 01, 2012 ) New York, NY -- The recent pullback of Immunocellular Therapeutics (IMUC) shares may have opened up a buying opportunity, according to VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors.
Immunocellular Therapeutics (IMUC) has already posted some significant gains since the opening days of 2012 - easily blowing through the two dollar mark before hitting three for a time - and although the stock has held strong through recent bouts of broad market volatility, shares experienced a mild pullback over the past few trading sessions. Any such moves in line with Monday's four percent dip, however, may be viewed as nothing more than a potential opportunity to accumulate as IMUC may posess enough early-year momentum to not only sustain the current higher prices, but also to propel shares higher as numerous still-pending developments play out.
Much of the fuel behind the fire that sparked this year's dramatic price run is due to the success demonstrated by the company's immunotherapeutic cancer-fighting technology that trains one's immune system to attack cancer cells at the stem, thereby eliminating - or at least greatly reducing - the threat that the cancer will grow and spread. This technology has been put to the test with ICT-107 in the treatment of gliblastoma, a very deadly form of brain cancer. Early results have been highly encouraging, and results from an ongoing Phase II trial should start rolling in on an interim basis within the year.
The prospects of those results - including the potential prospects of hearing some additional, longer-term follow-up results from already-treated patients - has piqued investor interest of late. Other solid developments on the stock side have also augmented the anticipation of the clinical results, such as the infusion of institutional interest earlier this year and a pending move to one of the larger trading exchanges that would add additional credibility to the company and attract a broader scope of investors.
For full report visit: http://vfcsstockhouse.com/blog/article/-immunocellular-therapeutics-imuc-any-pullback-may-mean-opportunity
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
